NTRA Stock Overview A diagnostics company, develops and commercializes molecular testing services worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Natera Historical stock prices Current Share Price US$161.99 52 Week High US$175.63 52 Week Low US$58.53 Beta 1.64 1 Month Change -3.15% 3 Month Change 31.61% 1 Year Change 166.26% 3 Year Change 77.52% 5 Year Change 383.12% Change since IPO 612.36%
Recent News & Updates
Co-Founder & Director recently sold US$953k worth of stock Dec 23
Co-Founder & Executive Chairman notifies of intention to sell stock Dec 15
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer Dec 12
Lead Independent Director recently sold US$15m worth of stock Dec 06
Lead Independent Director notifies of intention to sell stock Dec 03
Natera, Inc. Announces Clinical Validation Study on Natera's Fetal RhD NIPT Published in Obstetrics & Gynecology Dec 03 See more updates
Co-Founder & Director recently sold US$953k worth of stock Dec 23
Co-Founder & Executive Chairman notifies of intention to sell stock Dec 15
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer Dec 12
Lead Independent Director recently sold US$15m worth of stock Dec 06
Lead Independent Director notifies of intention to sell stock Dec 03
Natera, Inc. Announces Clinical Validation Study on Natera's Fetal RhD NIPT Published in Obstetrics & Gynecology Dec 03 KAS Team Wins $292.5 Million in Jury Trial of Guardant Health Inc. Versus Natera, Inc
Forecast to breakeven in 2026 Nov 27
Federal Court Jury Issues Unanimous Verdict That Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™ Nov 26
Independent Director recently sold US$1.5m worth of stock Nov 24
Independent Director exercised options and sold US$4.6m worth of stock Nov 23
Subdued Growth No Barrier To Natera, Inc. (NASDAQ:NTRA) With Shares Advancing 25% Nov 19
No longer forecast to breakeven Nov 18
Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$158 Nov 15
Co-Founder & Director notifies of intention to sell stock Nov 14
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 13
Natera Announces Completion of Signatera Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer Nov 12
Natera, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 01
Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds Oct 31
Now 22% overvalued after recent price rise Oct 29
Co-Founder & Director notifies of intention to sell stock Sep 20
Natera, Inc.'s (NASDAQ:NTRA) Intrinsic Value Is Potentially 20% Below Its Share Price Sep 18
Natera, Inc. Announces New Data from the GALAXY Arm of the Ongoing Circulate-Japan Trial at the 2024 Congress of the European Society for Medical Oncology in Barcelona, Spain Sep 15
Now 23% overvalued after recent price rise Sep 11
Consensus estimates of losses per share improve by 20% Aug 16
Forecast to breakeven in 2026 Aug 13
Co-Founder & Executive Chairman exercised options to buy US$22m worth of stock. Aug 12
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 09
Forecast to breakeven in 2026 Aug 09
Natera, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 31
CEO & Director notifies of intention to sell stock Jul 05
Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet? Jul 05
Natera, Inc. Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer Jun 27
CEO & Director notifies of intention to sell stock Jun 19
Natera, Inc. Launches Differentiated New Feature for Prospera Heart Test, Enhancing Detection of Rejection for Transplant Patients Jun 18
Natera: Overdue For A Breather Jun 03
New minor risk - Insider selling Jun 02
Secretary & Chief Legal Officer notifies of intention to sell stock May 13
Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$119 May 12
Price target increased by 9.0% to US$113 May 12
Natera, Inc. Provides Earnings Guidance for the Year 2024 May 11
First quarter 2024 earnings released: US$0.56 loss per share (vs US$1.23 loss in 1Q 2023) May 10 Natera, Inc. to Report Q1, 2024 Results on May 09, 2024
Natera, Inc., Annual General Meeting, Jun 12, 2024 Apr 26
CEO & Director notifies of intention to sell stock Apr 17
Now 20% undervalued Apr 12
Natera, Inc. Announces Publication of Larger Prospective dd-cfDNA Study in Kidney Transplantation Apr 12
Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients Apr 10
Co-Founder & Director notifies of intention to sell stock Apr 05
Natera, Inc. and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (Modern) A Randomized, Phase Ii/Iii Adjuvant Trial in Urothelial Cancer Apr 02
Is There An Opportunity With Natera, Inc.'s (NASDAQ:NTRA) 41% Undervaluation? Mar 30
Natera: Capitalizing On The Positive Momentum Of Personalized Medicine Mar 22
Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™? in Stage II Colorectal Cancer Mar 19
CEO & Director notifies of intention to sell stock Mar 18
Consensus estimates of losses per share improve by 11% Mar 07
Is Natera (NASDAQ:NTRA) A Risky Investment? Mar 03
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 01
Price target increased by 12% to US$86.94 Feb 29 Natera, Inc. Provides Earnings Guidance for the Year 2024
Natera, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 21
Independent Director notifies of intention to sell stock Feb 19
Chief Financial Officer notifies of intention to sell stock Feb 04
Natera, Inc. Announces New Study Demonstrates Signatera's Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer Jan 30
Co-Founder & Director notifies of intention to sell stock Jan 24
Natera, Inc. Provides Update on Ravgen Trial Jan 17
Natera, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2023 Jan 10
Natera Announces New Study Highlighting the Benefits of Signatera's Unique Method of Quantifying ctDNA Dec 21
Natera, Inc. Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023 Dec 06
Natera, Inc. Raises Revenue Guidance for the Full Year 2023 Nov 10
Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat Nov 10
Natera, Inc. Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer Nov 09
Natera's RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight in Chronic Kidney Disease Nov 03
Co-Founder & Director notifies of intention to sell stock Oct 26
Natera, Inc. Announces Updated Data from the Galaxy Arm of the Circulate-Japan Trial Oct 23
Natera, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Oct 21
Natera, Inc. to Present New Signatera MRD Data At ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study Oct 17
Natera, Inc. Announces New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early Oct 06 Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera
Natera, Inc. Announces Senior Leadership Appointments Sep 19
Natera, Inc. Announces Expanded I-Spy 2 Collaboration to Evaluate Signatera™? for Breast Cancer Patients in the Neoadjuvant Setting Sep 15 Natera, Inc. has completed a Follow-on Equity Offering in the amount of $250.25 million. Sep 08
Natera, Inc. has completed a Follow-on Equity Offering in the amount of $250.25 million. Sep 07
Co-Founder & Director notifies of intention to sell stock Sep 04
Natera's Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage Aug 17
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 04
Natera, Inc. Revises Earnings Guidance for the Year 2023 Aug 04 Natera Announces Completion of Enrollment to the Randomized, Phase III Altair Trial of Signatera in Colorectal Cancer
Co-Founder & Director notifies of intention to sell stock Jul 24
United States District Court for the District of Delaware Issues Favorable Ruling for Natera, Inc. in False Advertising Trial Against CareDx, Inc Jul 18
Natera, Inc.(NasdaqGS:NTRA) dropped from Russell 1000 Value Index Jun 25 Shareholder Returns NTRA US Biotechs US Market 7D -5.2% -3.3% -2.2% 1Y 166.3% -1.9% 23.9%
See full shareholder returns
Return vs Market: NTRA exceeded the US Market which returned 23.4% over the past year.
Price Volatility Is NTRA's price volatile compared to industry and market? NTRA volatility NTRA Average Weekly Movement 7.7% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: NTRA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NTRA's weekly volatility (8%) has been stable over the past year.
About the Company Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test.
Show more Natera, Inc. Fundamentals Summary How do Natera's earnings and revenue compare to its market cap? NTRA fundamental statistics Market cap US$21.37b Earnings (TTM ) -US$214.69m Revenue (TTM ) US$1.53b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NTRA income statement (TTM ) Revenue US$1.53b Cost of Revenue US$648.58m Gross Profit US$883.38m Other Expenses US$1.10b Earnings -US$214.69m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.63 Gross Margin 57.66% Net Profit Margin -14.01% Debt/Equity Ratio 41.8%
How did NTRA perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 04:26 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Natera, Inc. is covered by 27 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Catherine Ramsey Schulte Baird Raymond Myers Benchmark Company Navann Ty Dietschi BNP Paribas Exane
Show 24 more analysts 
